A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.

被引：0
|
作者：
Kim, Won Seog
Yoon, Dok Hyun
Song, Yuqin
Yang, Haiyan
Cao, Junning
Ji, Dongmei
Koh, Youngil
Jing, Hongmei
Eom, Hyeon Seok
Kwak, Jae-Yong
Lee, Won-Sik
Lee, Jong Seok
Shin, Ho-Jin
Jin, Jie
Wang, Mei
Li, Jingrun
Huang, Xubin
Deng, Xueyuan
Yang, Zhenfan
Zhu, Jun
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[7] Peking Univ Third Hosp, Beijing, Peoples R China
[8] Natl Canc Ctr, Goyang, South Korea
[9] Chonbuk Natl Univ Hosp, Jeonju Si, South Korea
[10] Inje Univ, Busan Paik Hosp, Busan, South Korea
[11] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[12] Pusan Natl Univ Hosp, Pusan, South Korea
[13] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Dizal Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7563
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
    Song, Y.
    Yoon, D. H.
    Yang, H.
    Cao, J.
    Ji, D.
    Koh, Y.
    Jing, H.
    Eom, H.
    Kwak, J.
    Lee, W.
    Lee, J.
    Shin, H.
    Jin, J.
    Wang, M.
    Yang, Z.
    Kim, W. S.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 (11) : 1055 - 1063
  • [2] A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T-Cell Lymphoma
    Kim, Won-Seog
    Yoon, Dok-Hyun
    Eom, Hyeon-Seok
    Koh, Youngil
    Kwak, Jae-Yong
    Lee, Won-Sik
    Lee, Jong-Seok
    Shin, Ho-Jin
    Song, Yuqin
    Yang, Haiyan
    Wang, Mei
    Li, Jingrun
    Huang, Xubin
    Deng, Xueyuan
    Chen, Kan
    Yang, Zhenfan
    Zhu, Jun
    BLOOD, 2020, 136
  • [3] Golidocitinib favorable for relapsed/refractory T-cell lymphoma
    Nierengarten, Mary Beth
    CANCER, 2024, 130 (08) : 1191 - 1192
  • [4] Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.
    Barta, Stefan K.
    Zain, Jasmine M.
    Smith, Sonali M.
    Ruan, Jia
    Fung, Henry C.
    Tan, Carlyn R.
    Yang, Yibin
    Alpaugh, R. Katherine
    Ross, Eric A.
    Campbell, Kerry S.
    Khan, Nadia
    Fisher, Richard I.
    Oki, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory T-cell lymphoma.
    Zinzani, PL
    Tani, M
    Stefoni, V
    Alinari, L
    Marchi, E
    Fina, M
    Baccarani, M
    BLOOD, 2005, 106 (11) : 271B - 271B
  • [6] Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Maeda, Yoshinobu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (10): : 2061 - 2068
  • [7] A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
    Van den Neste, Eric
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne S.
    Bailly, Sarah
    Knoops, Laurent
    Morschhauser, Franck
    HAEMATOLOGICA, 2018, 103 (05) : 840 - 848
  • [8] PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/ REFRACTORY PERIPHERAL T-CELL LYMPHOMA
    Suzuki, R.
    Hyo, R.
    Kim, W. S.
    Tsukamoto, N.
    Maeda, Y.
    Masaki, Y.
    Sakai, R.
    Masunari, T.
    Niitsu, N.
    Ishida, F.
    Nakamura, S.
    Suzumiya, J.
    HAEMATOLOGICA, 2015, 100 : 401 - 401
  • [9] A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Bennani, N. Nora
    Pederson, Levi D.
    Atherton, Pamela
    Micallef, Ivana
    Colgan, Joseph P.
    Thanarajasingam, Gita
    Nowakowski, Grzegorz
    Witzig, Thomas E.
    Feldman, Andrew L.
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [10] A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Wu, Tao
    Yang, Haiyan
    Wang, Zheng
    Li, Zhiming
    Qiu, Lugui
    Bao, Hanying
    Xu, Zusheng
    Shu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345